Skip to main content

Home/ health information/ Group items tagged ABPI-Guidelines

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

ABPI suspends Novo Nordisk's membership for two years - 0 views

www.pharmacy.biz/disks-membership-for-two-years

ABPI-news pharmacy-business abpi-complaints Novo-nordisk-complaints abpi-two-years-membership ABPI-Code-of-Practice ABPI-Guidelines ABPI-guidelines-for-clinical-trials

shared by pharmacybiz on 21 Mar 23 - No Cached
  • pharmacybiz on 21 Mar 23
     
    The Association of the British Pharmaceutical Industry (ABPI) has suspended the membership of Novo Nordisk for two years due to serious breaches of its Code of Practice. The action was taken by the ABPI Board following an investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the ABPI Code of Practice, including Clause 2 which deals with actions "likely to bring discredit on, or reduce confidence in, the pharmaceutical industry". Having considered the case and requesting a further detailed audit of Novo Nordisk's compliance processes, the ABPI Board decided to suspend Novo Nordisk from ABPI membership. Susan Rienow, President-Elect, ABPI, said: "The ABPI Board has carefully considered the PMCPA's case report into Novo Nordisk and the subsequent audit of their compliance procedures. "The Board expressed significant concern about Novo Nordisk's compliance activities and the very serious issues identified. As a result, the ABPI Board have taken the decision to suspend Novo Nordisk from ABPI membership.
pharmacybiz

ABPI welcomes NICE's guidance on value of new antibiotics - 0 views

www.pharmacy.biz/ce-on-value-of-new-antibiotics

NICE-guidelines-antibiotics Guidelines-for-prescribing-antibiotics pharmacy-business Antibiotic-prescribing-guidelines-UK Antibiotic-guidelines-NICE

shared by pharmacybiz on 18 Apr 22 - No Cached
  • pharmacybiz on 18 Apr 22
     
    The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.
1 - 2 of 2
Showing 20▼ items per page